Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Intrathecal Baclofen for Stiff-Person Syndrome: Life-Threatening Intermittent Catheter Leakage
Neurol 60:1976-1978, Bardutzky,J.,et al, 2003
Severe Myotonic Crisis Resembling Malignant Hyperthermia
Neurol 104:e213497, Wadhwani,A.R.,et al, 2025
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024
Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017
Corticosteroid-Induced Paraplegia - A Diagnostic Clue for Spinal Dural Arterial Venous Fistula
JAMA Neurol 72:833-834, Hocker, S., 2015
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Fungal Infections Associated with Contaminated Methylprednisolone Injections - Preliminary Report
NEJM 368:2495-2509, Kauffman, C.,et al, 2013
Early Child Development and Exposure to Antiepileptic Drugs Prenatally and Through Breastfeeding
JAMA Neurol 70:1367-1374, Veiby, G.,et al, 2013
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Fatal Varicella-Zoster Virus Vasculopathy Associated with Adalimumab Therapy
Arch Neurol 69:1193-1196, Baek, W.,et al, 2012
Child Development Following In Utero Exposure: Levetiracetam vs Sodium Valproate
Neurol 76:383-389, Shallcross,R.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Reversible Cerebral Vasoconstriction Syndrome
Pract Neurol 9:256-267, Ducros,A. &Bousser,M.-G., 2009
Polymyalgia Rheumatica
BMJ 336:765-769, Michet,C.J. &Matteson,E.L., 2008
Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis
Radiology 242:647-649, Kuo,P.H.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Acute Disseminated Encephalomyelitis
Arch Neurol 62:1673-1680, Menge,T.,et al, 2005
Oral Antispastic Drugs in Nonprogressive Neurologic Diseases
Neurol 63:1357-1363, Montane,E.,et al, 2004
Intrathecal Baclofen Withdrawal Mimicking Sepsis
J Emerg Med 24:423-427, Kao,L.W.,e tal, 2003
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
Valproate Embryopathy in Three Sets of Siblings: Further Proof of Hereditary Susceptibility
Neurol 59:630-633, Malm,H.,et al, 2002
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Psychiatric Emergencies, The Neuroleptic Malignant and Serotonin Syndromes
Emerg Med Clin North Am 18:317-325, Carbone,J.R., 2000
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Near-Fatal Heat Stroke During the 1995 Heat Wave in Chicago
Ann Int Med 129:173-181, Damatte,J.E.,et al, 1998
Valproic Acid Hepatic Fatalities. III. U. S. Experience Since 1986
Neurol 46:465-469, Bryant,A.E.&Dreifuss,F., 1996
Progressive Deterioration of Intellect and Motor Function Occurring Several Decades after Cranial Irradiation
ARch Neurol 53:814-818, Duffey,P.,et al, 1996
Serotonin Syndrome
Neurol 45:219-223, Bodner,R.A.,et al, 1995
The Eosinophilia-Myalgia Syndrome:Status of 205 Patients and Results of Treatment 2 Years After Onset
Ann Int Med 122:851-855, Hertzman,P.A.,et al, 1995
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Tizanidine Treatment of Spasticity Caused by Multiple Sclerosis:Results of a Double-Blinded, Placebo-Controlled Trial
Neurol 44:S34-S43, Smith,C.,et al, 1994
Efficacy and Safety of Tizanidine in the Treatment of Spasticity in Patients with Spinal Cord Injury
Neurol 44:S44-S52, Nance,P.W.,et al, 1994
The Nondystrophic Myotonias
In Myology, McGraw-Hill, 2nd Ed, Ch49, p1291-13024., Rudel,R.,et al, 1994